Piper Sandler Initiates RxSight(RXST.US) With Hold Rating, Announces Target Price $18
Needham Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $22
UBS Downgrades RxSight(RXST.US) to Hold Rating, Cuts Target Price to $16
UBS Downgrades RxSight to Neutral From Buy, Cuts Price Target to $16 From $45
RxSight Is Maintained at Buy by Needham
RxSight's Market Challenges and Revised Growth Projections Lead to Hold Rating
RxSight Price Target Cut to $17.00/Share From $22.00 by Wells Fargo
RxSight Is Maintained at Equal-Weight by Wells Fargo
RxSight Analyst Ratings
Wells Fargo Maintains RxSight(RXST.US) With Hold Rating, Cuts Target Price to $17
Analysts Are Neutral on Top Healthcare Stocks: RxSight (RXST), Johnson & Johnson (JNJ)
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $22 to $43
JP Morgan Downgrades RxSight to Underweight, Lowers Price Target to $17
RxSight Is Maintained at Equal-Weight by Wells Fargo
RxSight Downgraded to Underperform From Buy at BofA
RxSight Analyst Ratings
Stifel Nicolaus Sticks to Their Hold Rating for RxSight (RXST)
RxSight's Growth Potential Amid Challenges: A Buy Recommendation by David Saxon
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $36
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $36